ObesityNCT02498002
Impacts of Intermittent Fasting on Energy Balance and Associated Health Outcomes
A study testing Physical Activity Monitoring (Actiheart), Energy Intake Monitoring and Body Weight Monitoring in people with Obesity and Type 2 Diabetes, run by University of Bath at 1 site in United Kingdom.
Trial summary
Obesity is a global concern with links to conditions such as diabetes. Historically, these conditions have been managed by reducing energy intake on a daily basis, which is often hampered by low adherence rates and compensatory reductions in physical activity. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Obesity, Type 2 Diabetes
- What is being tested?
- Physical Activity Monitoring (Actiheart), Energy Intake Monitoring and Body Weight Monitoring
- Type of treatment
- Injection or infusion, Medical device, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 54 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- May 2015to 28 Sep 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Body Mass Index of 20.5 kg/m2 or greater
- Stable body weight for preceding three months (<3 kg increase or decrease)
- Able and willing to safely comply with study procedures
- Be able to attend the laboratory and willing to participate in necessary protocols
- Be willing to undertake the durations of fasting required by the study
- Have the capacity and willingness to provide informed consent (oral and written)
Who cannot join
- Have a body weight greater than 120 kg
- Will be undertaking any other fasting practices during their participation in the study (can enrol once stable weight returns after fasting is completed)
- Currently engaged in or planning to engage in another weight management programme (e.g. weight watchers) or exercise programme (e.g. hypertrophy training or marathon training) during the study
- Have previously suffered or are suffering from an eating disorder as assessed using the Eating Disorder Examination Questionnaire, Version 6.0 (Fairburn \& Beglin, 2008)
- Have been diagnosed with either type 1 or type 2 diabetes
- Undertaking any form of medical treatment which may interfere with study variables (e.g. chemotherapy, liposuction, taking metformin, statins/other lipid-lowering medications)
Show all 13Show fewer
- Are peri-menopausal or menopausal (absence of menses for 3-24 months)
- Pregnant, recently pregnant (within last 6 months), planning to become pregnant (within next six months), or currently breastfeeding.
- Have donated more than 500 ml of blood in the last three months before the initial laboratory visit
- Lack of metal capacity or language skills to independently understand/follow the study protocol
- Physical disability which impacts study variables or ability to independently follow study protocol (e.g. paralysis)
- Cannot consume test meals due to intolerances (i.e. lactose)
- Report medical contraindications on the 'Physical Activity Readiness Questionnaire' and are unable to obtain medical approval for the treadmill test.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Impacts of Intermittent Fasting in Adults on Energy Balance, Body Composition, Postprandial Hormone Profiles and Gene Expression in Adipose Tissue
Obesity is a global concern with links to conditions such as diabetes. Historically, these conditions have been managed by reducing energy intake on a daily basis, which is often hampered by low adherence rates and compensatory reductions in physical activity. Intermittent fasting (IMF) has become popular as an alternative method of weight loss, where periods of normal eating are punctuated by days of fasting. However, despite its popularity, IMF is scarcely examined within the literature.
This study will examine the impact of IMF on energy balance and the associated health outcomes relating to conditions such as diabetes. To achieve this, 36 lean adults and 36 overweight/obese adults will be recruited, excluding those with conditions which may be adversely affected by fasting. Once enrolled, participants will complete a one month control phase, incorporating 12 days of diet and activity monitoring, to ensure their weight is stable before moving in to the intervention phase.
Read more
The intervention phase will begin with a lab protocol designed to examine body composition, resting metabolic rate and metabolic responses to two successive meals. Once completed, participants will be randomised to one of three diets which are listed below. Comparing the changes seen with diets 1 and 2 will provide the first direct comparison of IMF against more conventional strategies, while diet 3 will allow us to ascertain the role of weight loss in mediating any effects of IMF.
- Daily calorie restriction - Reduce energy intake by 25% on a daily basis
- IMF with weight loss - Alternate between 24 hour cycles of fasting and feeding with 150% of normal intake when feeding
- IMF without weight loss - Alternate between 24 hour cycles of fasting and feeding with 200% of normal intake when feeding
All three diets will last for 20 consecutive days, with transitions between each 24 hour diet cycle occurring at 15:00 each day to allow at least one main meal per day. When fasting, participants will only be permitted water and black tea/coffee to eliminate energy intake. Once again physical activity and diet will be monitored for 12 days during the intervention to examine changes in energy expenditure and ensure compliance.
Having completed all 20 diet cycles participants will return to the laboratory to repeat the protocol described earlier. Comparing these results against the values seen before the intervention will then allow the effects of IMF to be identified and compared.
Read the detailed description
Recruitment
Local advertising in the form of posters will distributed throughout the research institution, nearby organisations and the city of Bath. The posters will encourage interested persons to contact the chief investigator to receive more information on what the study will involve. The research team will be looking to recruit 72 (36 lean, 36 overweight/obese) individuals who satisfy the entry criteria (discussed later).
Enrolment
Potential volunteers will use the contact details provided in advertising materials to express their interest to the research team who will then provide them with a copy of the participant information sheet to read through at their convenience. Those interested in participating will then be invited to a pre-enrolment consultation where they will be given the opportunity to ask any questions they may have about the study before being screened for the inclusion and exclusion criteria. This will involve measurements of weight and height, as well as the completion of an entry criteria questionnaire, the Eating Disorder Examination Questionnaire and the Physical Activity Readiness Questionnaire. Providing they satisfy the relevant criteria they will be talked through the study and before being asked to complete an informed consent form. As part of this, the procedure for an adipose tissue biopsy will be discussed with the participant and they will be asked to decide whether or not they would like to include this as it is an optional test.
Baseline Lab Protocol (LAB 1)
Having formally enrolled in the study, participants will be invited to begin their involvement in the study with a 60 minute visit to the University of Bath following a 12 hour fast. During this visit, the researcher will obtain a urine sample to check hydration levels using an Osmometer, before taking measurements of height, weight and waist circumference. A fasting blood sample will also be obtained using venepuncture to measure resting levels of key hormones and metabolites. To conclude this visit participants will be asked to perform a submaximal exercise test to calibrate the 'Actiheart' monitor being used throughout the study to measure physical activity energy expenditure. For this, participants will be asked to remain on a treadmill as the intensity increases over the following four stages:
- Stage 1 - level walking at 3.2 km/h
- Stage 2 - brisk walking at 5.2 km/h
- Stage 3 - brisk walking at 5.8 km/h with a steep gradient of +10.2%
- Stage 4 - level running at 12.5 km/h
Stage 4 will only be included for those who are formal exercisers, as non-exercisers are unlikely to be doing this kind of activity in their normal routine rendering a calibration at this intensity unnecessary. Formal exercisers will be identified using the entry criteria questionnaire. In addition, the treadmill protocol will be stopped earlier if the participant asks to stop or if their heart rate exceeds 85% of their age-predicted maximum.
Monitoring Phase
Before leaving the lab, participants will be provided with an Actiheart monitor, a small device applied to the chest which measures physical activity by recording heart rate and movement every minute. They will also be provided with a set of kitchen scales and a log book to create a weighed record of their food and fluid intake and a set of body weight scales to track their weight and help keep it stable.
During the four week monitoring phase, participants will be asked to complete four 3-day monitoring periods, each comprising two weekdays and one weekend day whilst they continue in their normal dietary and exercise habits. The researchers will arrange the collection and delivery of monitoring equipment where necessary. The purpose of this is firstly to ensure weight stability to minimise any confounding influences, secondly to provide accurate baseline values for key variables such as physical activity, and finally to ensure the dietary records provided are a valid reflection of habitual intake.
Provided the data obtained in the control phase satisfies the relevant reliability criteria, participants will be invited to return to the physiology lab at least four weeks after their first visit. In preparation for this, participants will be asked to avoid strenuous exercise, alcohol and caffeine, before fasting overnight until they arrive at the lab the following morning.
Pre-Intervention Lab Protocol (LAB 2)
Before beginning their intervention participants will be asked to attend a pre-intervention lab protocol, as outlined below. Female participants will be asked to schedule this so that it coincides with the follicular phase of their menstrual cycle (3-10 days after the onset of menses) as this is when their hormone profiles are at their most stable.
On the day of their visit participants will be asked to consume one pint of water at 06:30 before preparing themselves to arrive at the lab by 07:30, wearing light clothes (i.e. shorts, t-shirt) with no metal components or jewellery. They will then need to provide a small urine sample to check hydration levels before measurements of height, weight and waist circumference are taken (NOTE: If weight varies by more than 1.0 kilograms compared to their baseline measurement they may be asked to repeat the monitoring phase).
At 07:45 participants will be asked to lie in a semi-recumbent position and rest for 30 minutes. This is in preparation for the measurement of resting metabolic rate and substrate oxidation which will be completed at 08:15 over three 5-minute periods using indirect calorimetry while the participant remains rested. Following this an intravenous cannula will be fitted to the antecubital vein at the elbow for blood sampling throughout the visit. At this point a 12 ml fasting blood sample will also be drawn to measure resting levels of key metabolites (e.g. glucose, insulin, cholesterol, leptin, ghrelin, etc.).
At 08:45, participants who have elected to include the adipose tissue biopsy will undergo this procedure. If included, an area on the side of the abdomen just above the waistband will be sterilised and injected with an anaesthetic (Lidocaine Hydrochloride) to numb the area. Using a larger needle a 0.5 gram sample of adipose tissue will then be taken from just below the skin. There will some bruising, but if left to heal there should be no scarring. Those who choose not to include this biopsy will simply continue resting.
At 09:00 participants will be asked to complete visual analogue scales (VAS) which will provide subjective measures of appetite, fullness and desire to eat. Immediately after this, participants will be provided with a test breakfast of instant porridge made with whole milk and sugar which they will need to consume within 10 minutes. Key measures will then be taken at the following intervals:
- 12 ml blood sample - 15, 30, 45, 60, 90, 120, 180
- Visual analogue scales - 30, 60, 90, 120, 150, 180
- Metabolic rate (indirect calorimetry) - 60. 120, 180 (Note: total urine output will also be quantified throughout the postprandial period to adjust substrate oxidation values for protein oxidation)
At 12:05 participants will be asked to place the hand of their cannulated arm in a padded Perspex box which will be heated to 55 degrees. This is to allow the venous blood to be arterialised which will provide a better indication of whole body glucose metabolism in the test which follows. At 12:15 a 7 ml blood sample will be drawn after which the participant will be asked to consume a milkshake which provides 33% of their energy requirements. Blood samples (7 ml) will then be drawn every 15 minutes for the ensuing two hours to test for the presence of a second meal effect. At 14:15 the final blood sample for this visit will be drawn and the cannula will be removed.
To conclude the pre-intervention protocol participants will be taken to a separate lab for a dual-energy x-ray absorptiometry (DEXA) scan. This is a specialized form of whole-body scan which measures how a person's weight is distributed between fat and muscle tissue. It takes approximately eight minutes and requires the participant to lie still throughout. It does administer a small dose of ionizing radiation, but this is equivalent to 7 microSieverts which is accompanied by a risk of detrimental radiation effects in the region of 1 in 10 million. The application of this method has been approved in this study by an independent medical physics expert and a clinical radiation expert.
Intervention Phase
Before exiting the lab participants will be randomised to one of three treatment conditions outlined below. All three diet groups will last for 20 days in total, with transitions between each 24 hour cycle occurring at 15:00 each day, the idea being that it will allow them to consume at least one main meal per day in all cases. For the intermittent fasting groups (IMF), please note that during fasted cycles participants will be asked to only consume water and black tea/coffee with no milk or sugar. During feeding cycles, and throughout the daily calorie restriction diet, participants will be asked to recreate their control phase diet record with appropriately modified quantities to give 75%, 150% or 200% of their normal calorie intake in accordance with the group they are assigned to. Where recreation is not possible, participants will be asked to note the item that has been removed and/or the item that was added in a new diet record that will be provided before they leave the lab. Physical activity will also be monitored for the first and last week of the intervention using an Actiheart monitor to examine behavioural adaptations to the diets.
- Daily calorie restriction - Reduce energy intake by 25% on a daily basis
- IMF with weight loss - Alternate between 24 hour cycles of fasting and feeding with 150% of normal intake when feeding
- IMF without weight loss - Alternate between 24 hour cycles of fasting and feeding with 200% of normal intake when feeding
At 15:00 on the day of their initial lab visit, male participants will begin their assigned diet, although this can be postponed by up to one week if necessary. Female participants will be asked to delay this by six days in all cases in order to ensure their post-intervention lab visit falls within the same phase of their menstrual cycle to minimise the impact of monthly hormonal fluctuations.
Post-Intervention Lab Protocol (LAB 3)
Following the completion of 20 consecutive 24 hour dietary cycles, participants will return to their normal diet for one day (prescribed) whilst avoiding strenuous exercise, smoking, alcohol and caffeine, before fasting until they arrive at the lab the following morning for their post-intervention lab visit. Having consumed a pint of water at 06:30 and arrived at 07:30 in light clothing, participants will undergo the same lab protocol described earlier for their pre-intervention visit. However, instead of being randomised to a diet group they will be asked to complete a feedback questionnaire on their experience of the study.
Follow-up
Four weeks after their post-intervention lab visit participants will be invited to a feedback session to discuss all available results. The results from the meal test and the study as a whole will follow at a later date due to logistics and cost-effectiveness. Where convenient participants will also be asked to include a weight measurement to provide an indication of weight loss sustainability.
Aim
Once datasets are obtained for all 72 participants, the daily calorie restriction group will be compared against the IMF with weight loss group. This will permit the comparison of the effects of an IMF diet against the effects of a more conventional approach when matched for energy deficit. The final group, IMF without weight loss, will then highlight the relative contributions of weight loss and fasting-dependent mechanisms in producing any observed effects.
- Conditions
- Obesity, Type 2 Diabetes
- Being tested
- Physical Activity Monitoring (Actiheart), Energy Intake Monitoring, Body Weight Monitoring, Intravenous Cannulation, Adipose Tissue Biopsy
- Keywords
- Diet, Fasting, Intermittent Fasting, Alternate-day Fasting, Physical Activity, Glucose, Insulin, Appetite
- Medical subject headings
- Obesity, Diabetes Mellitus, Type 2, Fasting, Intermittent Fasting, Motor Activity, Insulin Resistance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Physical Activity Monitoring (Actiheart)Device
Monitor physical activity using an Actiheart monitor during the required periods.
Energy Intake MonitoringOther
Monitor energy intake by weighing and recording all foods/drinks consumed during the required periods.
Body Weight MonitoringOther
Monitor body weight during monitoring phase to ensure stability despite other monitoring activities.
Intravenous CannulationProcedure or surgery
Fitting of an intravenous cannula to a vein on the forearm for blood sampling during laboratory protocols.
Adipose Tissue BiopsyProcedure or surgery
This is an optional feature which if included involves the removal of a 0.5 gram sample of adipose tissue from just below the skin using a needle.
Lidocaine HydrochlorideDrug
The anaesthetic that will be used to numb the site of the adipose tissue biopsy in the event it is included.
Post-Prandial Meal TestsOther
Consume two successive meals with regular blood samples throughout the ensuing hours (2-3 hours each).
DEXA ScanRadiation
Undergo a dual energy x-ray absorptiometry scan to examine body composition.
Actiheart CalibrationOther
Submaximal treadmill test to calibrate monitoring equipment.
Daily Calorie RestrictionOther
Reduce energy intake by 25% on a daily basis.
Intermittent Fasting with Weight LossOther
Alternate between 24 hour cycles of fasting and feeding with 150% of normal intake when feeding.
Intermittent Fasting without Weight LossOther
Alternate between 24 hour cycles of fasting and feeding with 200% of normal intake when feeding.
| Study group | Role | What they receive |
|---|---|---|
| Daily Calorie Restriction (DCR) | Active comparator | During the intervention phase, participants randomised to this treatment condition will be asked to reduce their normal energy intake by 25% on a daily basis. Receives: Device: Physical Activity Monitoring (Actiheart); Other: Energy Intake Monitoring; Other: Body Weight Monitoring; Procedure: Intravenous Cannulation; Procedure: Adipose Tissue Biopsy; Drug: Lidocaine Hydrochloride; Other: Post-Prandial Meal Tests; Radiation: DEXA Scan; Other: Actiheart Calibration; Other: Daily Calorie Restriction |
| Fasting with Weight Loss (IMF-WL) | Experimental | During the intervention phase, participants randomised to this treatment condition will be asked to alternate between 24 hour cycles of feeding (consume 150% of normal energy intake) and fasting (no energy intake). Receives: Device: Physical Activity Monitoring (Actiheart); Other: Energy Intake Monitoring; Other: Body Weight Monitoring; Procedure: Intravenous Cannulation; Procedure: Adipose Tissue Biopsy; Drug: Lidocaine Hydrochloride; Other: Post-Prandial Meal Tests; Radiation: DEXA Scan; Other: Actiheart Calibration; Other: Intermittent Fasting with Weight Loss |
| Fasting without Weight Loss (IMF-WS) | Experimental | During the intervention phase, participants randomised to this treatment condition will be asked to alternate between 24 hour cycles of feeding (consume 200% of normal energy intake) and fasting (no energy intake). Receives: Device: Physical Activity Monitoring (Actiheart); Other: Energy Intake Monitoring; Other: Body Weight Monitoring; Procedure: Intravenous Cannulation; Procedure: Adipose Tissue Biopsy; Drug: Lidocaine Hydrochloride; Other: Post-Prandial Meal Tests; Radiation: DEXA Scan; Other: Actiheart Calibration; Other: Intermittent Fasting without Weight Loss |
What is being measured
The primary outcome is the main question the study is designed to answer.
Body Fat Percentage
Comparison of body fat percentage (measured by dual-energy x-ray absorptiometry) from pre-intervention time-point to post-intervention time-point.
Measured: Pre - Post (3 weeks)
Lean Body Mass
Comparison of lean body mass (measured by dual-energy x-ray absorptiometry) from pre-intervention time-point to post-intervention time-point.
Measured: Pre - Post (3 weeks)
Fasting Plasma Glucose Concentration
Comparison of glucose concentration in the blood plasma at rest across all three measurement points to ensure stability in the monitoring phase and examine change during the intervention phase.
Measured: Baseline - Pre - Post (7 weeks)
Fasting Plasma Insulin Concentration
Comparison of insulin concentration in the blood plasma at rest across all three measurement points to ensure stability in the monitoring phase and examine change during the intervention phase.
Measured: Baseline - Pre - Post (7 weeks)
Fasting Plasma Triglyceride Concentration
Comparison of triglyceride concentration in the blood plasma at rest across all three measurement points to ensure stability in the monitoring phase and examine change during the intervention phase.
Measured: Baseline - Pre - Post (7 weeks)
Fasting Total Cholesterol Concentration
Comparison of total cholesterol concentration in the blood plasma at rest across all three measurement points to ensure stability in the monitoring phase and examine change during the intervention phase.
Measured: Baseline - Pre - Post (7 weeks)
Fasting LDL Cholesterol Concentration
Comparison of LDL cholesterol concentration in the blood plasma at rest across all three measurement points to ensure stability in the monitoring phase and examine change during the intervention phase.
Measured: Baseline - Pre - Post (7 weeks)
Fasting HDL Cholesterol Concentration
Comparison of HDL cholesterol concentration in the blood plasma at rest across all three measurement points to ensure stability in the monitoring phase and examine change during the intervention phase.
Measured: Baseline - Pre - Post (7 weeks)
Fasting Leptin Concentration
Comparison of leptin concentration in the blood plasma at rest across all three measurement points to ensure stability in the monitoring phase and examine change during the intervention phase.
Measured: Baseline - Pre - Post (7 weeks)
Fasting Adiponectin Concentration
Comparison of adiponectin concentration in the blood plasma at rest across all three measurement points to ensure stability in the monitoring phase and examine change during the intervention phase.
Measured: Baseline - Pre - Post (7 weeks)
Fasting Resting Metabolic Rate
Comparison of resting metabolic rate (measured by indirect calorimetry) across all three measurement points to ensure stability in the monitoring phase and examine change during the intervention phase.
Measured: Baseline - Pre - Post (7 weeks)
Post-Prandial Glucose AUC
Comparison of the area under the plasma glucose curve seen during the 180 minute post-prandial period following a test meal conducted before and after the intervention phase.
Measured: Pre - Post (3 weeks)
Post-Prandial Insulin AUC
Comparison of the area under the plasma insulin curve seen during the 180 minute post-prandial period following a test meal conducted before and after the intervention phase.
Measured: Pre - Post (3 weeks)
Post-Prandial Ghrelin AUC
Comparison of the area under the plasma ghrelin curve seen during the 180 minute post-prandial period following a test meal conducted before and after the intervention phase.
Measured: Pre - Post (3 weeks)
Post-Prandial Peptide-YY AUC
Comparison of the area under the plasma peptide-YY curve seen during the 180 minute post-prandial period following a test meal conducted before and after the intervention phase.
Measured: Pre - Post (3 weeks)
Physical Activity Energy Expenditure
Comparison of the mean physical activity energy expenditure values recorded using the Actiheart monitor during the monitoring and intervention phase to see the impact of the three treatments on physically active behaviours.
Measured: Monitoring - Intervention (7 weeks)
Physical Activity Intensity
Comparison of the mean physical activity intensity values recorded using the Actiheart monitor during the monitoring and intervention phase to see the impact of the three treatments on physically active behaviours.
Measured: Monitoring - Intervention (7 weeks)
CLOCK Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
NPAS2 Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
PER1 Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
CRY1 Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
LEP Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
ADIPO-Q Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
IL-6 Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
TNF Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
LPL Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
FABP4 Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
PPARG Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
PPARGC1A Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
SREBP1C Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
FSP27 Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
PRKAA1 Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
ANGPTL4 Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
HSL Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
ATGL Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
PNPLA3 Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
CIDE-A Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
GLUT-4 Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
AKT2 Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
PDK4 Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
SIRT1 Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
SIRT3 Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
UCP2 Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
IGF1R Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
IRS1 Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
IRS2 Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
PIK3R1 Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
ChREBP Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
ACACA Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
FASN Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
ACADM Gene Expression in Subcutaneous Adipose Tissue
Measured: Pre - Post (3 weeks)
Secondary outcomes (7)
Fasting Carbohydrate Oxidation
Comparison of carbohydrate oxidation rate measured by indirect calorimetry before and after the intervention phase to examine the effect of the three treatment arms.
Measured: Pre - Post (3 weeks)
Fasting Lipid Oxidation
Comparison of lipid oxidation rate measured by indirect calorimetry before and after the intervention phase to examine the effect of the three treatment arms.
Measured: Pre - Post (3 weeks)
Fasting Protein Oxidation
Comparison of protein oxidation rate measured by indirect calorimetry before and after the intervention phase to examine the effect of the three treatment arms.
Measured: Pre - Post (3 weeks)
Post-Prandial Resting Metabolic Rate
Comparison of post-prandial metabolic rate measured 60, 120 and 180 minutes after a test meal by indirect calorimetry before and after the intervention phase to examine the effect of the three treatment arms.
Measured: Pre-intervention 60, 120 and 180 minutes after meal - post-intervention 60, 120 and 180 minutes after meal (3 weeks)
Post-Prandial Carbohydrate Oxidation
Comparison of post-prandial carbohydrate oxidation rate measured 60, 120 and 180 minutes after a test meal by indirect calorimetry before and after the intervention phase to examine the effect of the three treatment arms.
Measured: Pre-intervention 60, 120 and 180 minutes after meal - post-intervention 60, 120 and 180 minutes after meal (3 weeks)
Post-Prandial Lipid Oxidation
Comparison of post-prandial lipid oxidation rate measured 60, 120 and 180 minutes after a test meal by indirect calorimetry before and after the intervention phase to examine the effect of the three treatment arms.
Measured: Pre-intervention 60, 120 and 180 minutes after meal - post-intervention 60, 120 and 180 minutes after meal (3 weeks)
Post-Prandial Protein Oxidation
Comparison of post-prandial protein oxidation rate measured 60, 120 and 180 minutes after a test meal by indirect calorimetry before and after the intervention phase to examine the effect of the three treatment arms.
Measured: Pre-intervention 60, 120 and 180 minutes after meal - post-intervention 60, 120 and 180 minutes after meal (3 weeks)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jul 2015 (estimated)
- Study startMay 2015
- Primary completion4 Sep 2018
- Study completion28 Sep 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for ObesityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 54 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Bath
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, James Betts, University of Bath
- Investigators
- James A Betts, BSc., Ph.D, Principal investigator, Fellow of the American College of Sports Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02498002
- Sponsor's protocol ID
- IMF-02
- Status last verified
- Apr 2023
- First submitted
- 6 Jul 2015
- Last updated
- 18 Apr 2023
- Results posted
- No
- Data monitoring committee
- No
Publications
Templeman I, Thompson D, Gonzalez J, Walhin JP, Reeves S, Rogers PJ, Brunstrom JM, Karagounis LG, Tsintzas K, Betts JA. Intermittent fasting, energy balance and associated health outcomes in adults: study protocol for a randomised controlled trial. Trials. 2018 Feb 2;19(1):86. doi: 10.1186/s13063-018-2451-8.
PubMed 29394908
Study at a glance
From the registry record, last updated by the sponsor on 18 Apr 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impacts of Intermittent Fasting in Adults on Energy Balance, Body Composition, Postprandial Hormone Profiles and Gene Expression in Adipose Tissue
- ClinicalTrials.gov ID
- NCT02498002
- Acronym / sponsor ID
- IMF-02
- Conditions
- Obesity, Type 2 Diabetes
- Keywords
- Diet, Fasting, Intermittent Fasting, Alternate-day Fasting, Physical Activity, Glucose, Insulin, Appetite
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 54 participants (actual)
- Lead sponsor
- University of BathUniversity, hospital or other
- Study start
- May 2015 (actual)
- Primary completion
- 4 Sep 2018 (actual)
- Study completion
- 28 Sep 2018 (actual)
- First posted
- 15 Jul 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Obesity is a global concern with links to conditions such as diabetes. Historically, these conditions have been managed by reducing energy intake on a daily basis, which is often hampered by low adherence rates and compensatory reductions in physical activity. Intermittent fasting (IMF) has become popular as an alternative method of weight loss, where periods of normal eating are punctuated by days of fasting. However, despite its popularity, IMF is scarcely examined within the literature.
This study will examine the impact of IMF on energy balance and the associated health outcomes relating to conditions such as diabetes. To achieve this, 36 lean adults and 36 overweight/obese adults will be recruited, excluding those with conditions which may be adversely affected by fasting. Once enrolled, participants will complete a one month control phase, incorporating 12 days of diet and activity monitoring, to ensure their weight is stable before moving in to the intervention phase.
The intervention phase will begin with a lab protocol designed to examine body composition, resting metabolic rate and metabolic responses to two successive meals. Once completed, participants will be randomised to one of three diets which are listed below. Comparing the changes seen with diets 1 and 2 will provide the first direct comparison of IMF against more conventional strategies, while diet 3 will allow us to ascertain the role of weight loss in mediating any effects of IMF.
- Daily calorie restriction - Reduce energy intake by 25% on a daily basis
- IMF with weight loss - Alternate between 24 hour cycles of fasting and feeding with 150% of normal intake when feeding
- IMF without weight loss - Alternate between 24 hour cycles of fasting and feeding with 200% of normal intake when feeding
All three diets will last for 20 consecutive days, with transitions between each 24 hour diet cycle occurring at 15:00 each day to allow at least one main meal per day. When fasting, participants will only be permitted water and black tea/coffee to eliminate energy intake. Once again physical activity and diet will be monitored for 12 days during the intervention to examine changes in energy expenditure and ensure compliance.
Having completed all 20 diet cycles participants will return to the laboratory to repeat the protocol described earlier. Comparing these results against the values seen before the intervention will then allow the effects of IMF to be identified and compared.
Detailed description
Recruitment
Local advertising in the form of posters will distributed throughout the research institution, nearby organisations and the city of Bath. The posters will encourage interested persons to contact the chief investigator to receive more information on what the study will involve. The research team will be looking to recruit 72 (36 lean, 36 overweight/obese) individuals who satisfy the entry criteria (discussed later).
Enrolment
Potential volunteers will use the contact details provided in advertising materials to express their interest to the research team who will then provide them with a copy of the participant information sheet to read through at their convenience. Those interested in participating will then be invited to a pre-enrolment consultation where they will be given the opportunity to ask any questions they may have about the study before being screened for the inclusion and exclusion criteria. This will involve measurements of weight and height, as well as the completion of an entry criteria questionnaire, the Eating Disorder Examination Questionnaire and the Physical Activity Readiness Questionnaire. Providing they satisfy the relevant criteria they will be talked through the study and before being asked to complete an informed consent form. As part of this, the procedure for an adipose tissue biopsy will be discussed with the participant and they will be asked to decide whether or not they would like to include this as it is an optional test.
Baseline Lab Protocol (LAB 1)
Having formally enrolled in the study, participants will be invited to begin their involvement in the study with a 60 minute visit to the University of Bath following a 12 hour fast. During this visit, the researcher will obtain a urine sample to check hydration levels using an Osmometer, before taking measurements of height, weight and waist circumference. A fasting blood sample will also be obtained using venepuncture to measure resting levels of key hormones and metabolites. To conclude this visit participants will be asked to perform a submaximal exercise test to calibrate the 'Actiheart' monitor being used throughout the study to measure physical activity energy expenditure. For this, participants will be asked to remain on a treadmill as the intensity increases over the following four stages:
- Stage 1 - level walking at 3.2 km/h
- Stage 2 - brisk walking at 5.2 km/h
- Stage 3 - brisk walking at 5.8 km/h with a steep gradient of +10.2%
- Stage 4 - level running at 12.5 km/h
Stage 4 will only be included for those who are formal exercisers, as non-exercisers are unlikely to be doing this kind of activity in their normal routine rendering a calibration at this intensity unnecessary. Formal exercisers will be identified using the entry criteria questionnaire. In addition, the treadmill protocol will be stopped earlier if the participant asks to stop or if their heart rate exceeds 85% of their age-predicted maximum.
Monitoring Phase
Before leaving the lab, participants will be provided with an Actiheart monitor, a small device applied to the chest which measures physical activity by recording heart rate and movement every minute. They will also be provided with a set of kitchen scales and a log book to create a weighed record of their food and fluid intake and a set of body weight scales to track their weight and help keep it stable.
During the four week monitoring phase, participants will be asked to complete four 3-day monitoring periods, each comprising two weekdays and one weekend day whilst they continue in their normal dietary and exercise habits. The researchers will arrange the collection and delivery of monitoring equipment where necessary. The purpose of this is firstly to ensure weight stability to minimise any confounding influences, secondly to provide accurate baseline values for key variables such as physical activity, and finally to ensure the dietary records provided are a valid reflection of habitual intake.
Provided the data obtained in the control phase satisfies the relevant reliability criteria, participants will be invited to return to the physiology lab at least four weeks after their first visit. In preparation for this, participants will be asked to avoid strenuous exercise, alcohol and caffeine, before fasting overnight until they arrive at the lab the following morning.
Pre-Intervention Lab Protocol (LAB 2)
Before beginning their intervention participants will be asked to attend a pre-intervention lab protocol, as outlined below. Female participants will be asked to schedule this so that it coincides with the follicular phase of their menstrual cycle (3-10 days after the onset of menses) as this is when their hormone profiles are at their most stable.
On the day of their visit participants will be asked to consume one pint of water at 06:30 before preparing themselves to arrive at the lab by 07:30, wearing light clothes (i.e. shorts, t-shirt) with no metal components or jewellery. They will then need to provide a small urine sample to check hydration levels before measurements of height, weight and waist circumference are taken (NOTE: If weight varies by more than 1.0 kilograms compared to their baseline measurement they may be asked to repeat the monitoring phase).
At 07:45 participants will be asked to lie in a semi-recumbent position and rest for 30 minutes. This is in preparation for the measurement of resting metabolic rate and substrate oxidation which will be completed at 08:15 over three 5-minute periods using indirect calorimetry while the participant remains rested. Following this an intravenous cannula will be fitted to the antecubital vein at the elbow for blood sampling throughout the visit. At this point a 12 ml fasting blood sample will also be drawn to measure resting levels of key metabolites (e.g. glucose, insulin, cholesterol, leptin, ghrelin, etc.).
At 08:45, participants who have elected to include the adipose tissue biopsy will undergo this procedure. If included, an area on the side of the abdomen just above the waistband will be sterilised and injected with an anaesthetic (Lidocaine Hydrochloride) to numb the area. Using a larger needle a 0.5 gram sample of adipose tissue will then be taken from just below the skin. There will some bruising, but if left to heal there should be no scarring. Those who choose not to include this biopsy will simply continue resting.
At 09:00 participants will be asked to complete visual analogue scales (VAS) which will provide subjective measures of appetite, fullness and desire to eat. Immediately after this, participants will be provided with a test breakfast of instant porridge made with whole milk and sugar which they will need to consume within 10 minutes. Key measures will then be taken at the following intervals:
- 12 ml blood sample - 15, 30, 45, 60, 90, 120, 180
- Visual analogue scales - 30, 60, 90, 120, 150, 180
- Metabolic rate (indirect calorimetry) - 60. 120, 180 (Note: total urine output will also be quantified throughout the postprandial period to adjust substrate oxidation values for protein oxidation)
At 12:05 participants will be asked to place the hand of their cannulated arm in a padded Perspex box which will be heated to 55 degrees. This is to allow the venous blood to be arterialised which will provide a better indication of whole body glucose metabolism in the test which follows. At 12:15 a 7 ml blood sample will be drawn after which the participant will be asked to consume a milkshake which provides 33% of their energy requirements. Blood samples (7 ml) will then be drawn every 15 minutes for the ensuing two hours to test for the presence of a second meal effect. At 14:15 the final blood sample for this visit will be drawn and the cannula will be removed.
To conclude the pre-intervention protocol participants will be taken to a separate lab for a dual-energy x-ray absorptiometry (DEXA) scan. This is a specialized form of whole-body scan which measures how a person's weight is distributed between fat and muscle tissue. It takes approximately eight minutes and requires the participant to lie still throughout. It does administer a small dose of ionizing radiation, but this is equivalent to 7 microSieverts which is accompanied by a risk of detrimental radiation effects in the region of 1 in 10 million. The application of this method has been approved in this study by an independent medical physics expert and a clinical radiation expert.
Intervention Phase
Before exiting the lab participants will be randomised to one of three treatment conditions outlined below. All three diet groups will last for 20 days in total, with transitions between each 24 hour cycle occurring at 15:00 each day, the idea being that it will allow them to consume at least one main meal per day in all cases. For the intermittent fasting groups (IMF), please note that during fasted cycles participants will be asked to only consume water and black tea/coffee with no milk or sugar. During feeding cycles, and throughout the daily calorie restriction diet, participants will be asked to recreate their control phase diet record with appropriately modified quantities to give 75%, 150% or 200% of their normal calorie intake in accordance with the group they are assigned to. Where recreation is not possible, participants will be asked to note the item that has been removed and/or the item that was added in a new diet record that will be provided before they leave the lab. Physical activity will also be monitored for the first and last week of the intervention using an Actiheart monitor to examine behavioural adaptations to the diets.
- Daily calorie restriction - Reduce energy intake by 25% on a daily basis
- IMF with weight loss - Alternate between 24 hour cycles of fasting and feeding with 150% of normal intake when feeding
- IMF without weight loss - Alternate between 24 hour cycles of fasting and feeding with 200% of normal intake when feeding
At 15:00 on the day of their initial lab visit, male participants will begin their assigned diet, although this can be postponed by up to one week if necessary. Female participants will be asked to delay this by six days in all cases in order to ensure their post-intervention lab visit falls within the same phase of their menstrual cycle to minimise the impact of monthly hormonal fluctuations.
Post-Intervention Lab Protocol (LAB 3)
Following the completion of 20 consecutive 24 hour dietary cycles, participants will return to their normal diet for one day (prescribed) whilst avoiding strenuous exercise, smoking, alcohol and caffeine, before fasting until they arrive at the lab the following morning for their post-intervention lab visit. Having consumed a pint of water at 06:30 and arrived at 07:30 in light clothing, participants will undergo the same lab protocol described earlier for their pre-intervention visit. However, instead of being randomised to a diet group they will be asked to complete a feedback questionnaire on their experience of the study.
Follow-up
Four weeks after their post-intervention lab visit participants will be invited to a feedback session to discuss all available results. The results from the meal test and the study as a whole will follow at a later date due to logistics and cost-effectiveness. Where convenient participants will also be asked to include a weight measurement to provide an indication of weight loss sustainability.
Aim
Once datasets are obtained for all 72 participants, the daily calorie restriction group will be compared against the IMF with weight loss group. This will permit the comparison of the effects of an IMF diet against the effects of a more conventional approach when matched for energy deficit. The final group, IMF without weight loss, will then highlight the relative contributions of weight loss and fasting-dependent mechanisms in producing any observed effects.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Daily Calorie Restriction (DCR) | Active comparator | Device: Physical Activity Monitoring (Actiheart), Other: Energy Intake Monitoring, Other: Body Weight Monitoring, Procedure: Intravenous Cannulation, Procedure: Adipose Tissue Biopsy, Drug: Lidocaine Hydrochloride, Other: Post-Prandial Meal Tests, Radiation: DEXA Scan, Other: Actiheart Calibration, Other: Daily Calorie RestrictionDuring the intervention phase, participants randomised to this treatment condition will be asked to reduce their normal energy intake by 25% on a daily basis. |
| Fasting with Weight Loss (IMF-WL) | Experimental | Device: Physical Activity Monitoring (Actiheart), Other: Energy Intake Monitoring, Other: Body Weight Monitoring, Procedure: Intravenous Cannulation, Procedure: Adipose Tissue Biopsy, Drug: Lidocaine Hydrochloride, Other: Post-Prandial Meal Tests, Radiation: DEXA Scan, Other: Actiheart Calibration, Other: Intermittent Fasting with Weight LossDuring the intervention phase, participants randomised to this treatment condition will be asked to alternate between 24 hour cycles of feeding (consume 150% of normal energy intake) and fasting (no energy intake). |
| Fasting without Weight Loss (IMF-WS) | Experimental | Device: Physical Activity Monitoring (Actiheart), Other: Energy Intake Monitoring, Other: Body Weight Monitoring, Procedure: Intravenous Cannulation, Procedure: Adipose Tissue Biopsy, Drug: Lidocaine Hydrochloride, Other: Post-Prandial Meal Tests, Radiation: DEXA Scan, Other: Actiheart Calibration, Other: Intermittent Fasting without Weight LossDuring the intervention phase, participants randomised to this treatment condition will be asked to alternate between 24 hour cycles of feeding (consume 200% of normal energy intake) and fasting (no energy intake). |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Body Mass Index of 20.5 kg/m2 or greater
- Stable body weight for preceding three months (<3 kg increase or decrease)
- Able and willing to safely comply with study procedures
- Be able to attend the laboratory and willing to participate in necessary protocols
- Be willing to undertake the durations of fasting required by the study
Key exclusion criteria (13 listed)
- Have a body weight greater than 120 kg
- Will be undertaking any other fasting practices during their participation in the study (can enrol once stable weight returns after fasting is completed)
- Currently engaged in or planning to engage in another weight management programme (e.g. weight watchers) or exercise programme (e.g. hypertrophy training or marathon training) during the study
- Have previously suffered or are suffering from an eating disorder as assessed using the Eating Disorder Examination Questionnaire, Version 6.0 (Fairburn \& Beglin, 2008)
- Have been diagnosed with either type 1 or type 2 diabetes
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Physical Activity Monitoring (Actiheart)Monitor physical activity using an Actiheart monitor during the required periods. | Device | Daily Calorie Restriction (DCR), Fasting with Weight Loss (IMF-WL), Fasting without Weight Loss (IMF-WS) |
| Energy Intake MonitoringMonitor energy intake by weighing and recording all foods/drinks consumed during the required periods. | Other | Daily Calorie Restriction (DCR), Fasting with Weight Loss (IMF-WL), Fasting without Weight Loss (IMF-WS) |
| Body Weight MonitoringMonitor body weight during monitoring phase to ensure stability despite other monitoring activities. | Other | Daily Calorie Restriction (DCR), Fasting with Weight Loss (IMF-WL), Fasting without Weight Loss (IMF-WS) |
| Intravenous CannulationFitting of an intravenous cannula to a vein on the forearm for blood sampling during laboratory protocols. | Procedure or surgery | Daily Calorie Restriction (DCR), Fasting with Weight Loss (IMF-WL), Fasting without Weight Loss (IMF-WS) |
| Adipose Tissue BiopsyThis is an optional feature which if included involves the removal of a 0.5 gram sample of adipose tissue from just below the skin using a needle. | Procedure or surgery | Daily Calorie Restriction (DCR), Fasting with Weight Loss (IMF-WL), Fasting without Weight Loss (IMF-WS) |
| Lidocaine HydrochlorideThe anaesthetic that will be used to numb the site of the adipose tissue biopsy in the event it is included. | Drug | Daily Calorie Restriction (DCR), Fasting with Weight Loss (IMF-WL), Fasting without Weight Loss (IMF-WS) |
| Post-Prandial Meal TestsConsume two successive meals with regular blood samples throughout the ensuing hours (2-3 hours each). | Other | Daily Calorie Restriction (DCR), Fasting with Weight Loss (IMF-WL), Fasting without Weight Loss (IMF-WS) |
| DEXA ScanUndergo a dual energy x-ray absorptiometry scan to examine body composition. | Radiation | Daily Calorie Restriction (DCR), Fasting with Weight Loss (IMF-WL), Fasting without Weight Loss (IMF-WS) |
| Actiheart CalibrationSubmaximal treadmill test to calibrate monitoring equipment. | Other | Daily Calorie Restriction (DCR), Fasting with Weight Loss (IMF-WL), Fasting without Weight Loss (IMF-WS) |
| Daily Calorie RestrictionReduce energy intake by 25% on a daily basis. | Other | Daily Calorie Restriction (DCR) |
| Intermittent Fasting with Weight LossAlternate between 24 hour cycles of fasting and feeding with 150% of normal intake when feeding. | Other | Fasting with Weight Loss (IMF-WL) |
| Intermittent Fasting without Weight LossAlternate between 24 hour cycles of fasting and feeding with 200% of normal intake when feeding. | Other | Fasting without Weight Loss (IMF-WS) |
Primary outcome
Body Fat Percentage
Time frame: Pre - Post (3 weeks)
Comparison of body fat percentage (measured by dual-energy x-ray absorptiometry) from pre-intervention time-point to post-intervention time-point.
Lean Body Mass
Time frame: Pre - Post (3 weeks)
Comparison of lean body mass (measured by dual-energy x-ray absorptiometry) from pre-intervention time-point to post-intervention time-point.
Fasting Plasma Glucose Concentration
Time frame: Baseline - Pre - Post (7 weeks)
Comparison of glucose concentration in the blood plasma at rest across all three measurement points to ensure stability in the monitoring phase and examine change during the intervention phase.
Fasting Plasma Insulin Concentration
Time frame: Baseline - Pre - Post (7 weeks)
Comparison of insulin concentration in the blood plasma at rest across all three measurement points to ensure stability in the monitoring phase and examine change during the intervention phase.
Fasting Plasma Triglyceride Concentration
Time frame: Baseline - Pre - Post (7 weeks)
Comparison of triglyceride concentration in the blood plasma at rest across all three measurement points to ensure stability in the monitoring phase and examine change during the intervention phase.
Fasting Total Cholesterol Concentration
Time frame: Baseline - Pre - Post (7 weeks)
Comparison of total cholesterol concentration in the blood plasma at rest across all three measurement points to ensure stability in the monitoring phase and examine change during the intervention phase.
Fasting LDL Cholesterol Concentration
Time frame: Baseline - Pre - Post (7 weeks)
Comparison of LDL cholesterol concentration in the blood plasma at rest across all three measurement points to ensure stability in the monitoring phase and examine change during the intervention phase.
Fasting HDL Cholesterol Concentration
Time frame: Baseline - Pre - Post (7 weeks)
Comparison of HDL cholesterol concentration in the blood plasma at rest across all three measurement points to ensure stability in the monitoring phase and examine change during the intervention phase.
Fasting Leptin Concentration
Time frame: Baseline - Pre - Post (7 weeks)
Comparison of leptin concentration in the blood plasma at rest across all three measurement points to ensure stability in the monitoring phase and examine change during the intervention phase.
Fasting Adiponectin Concentration
Time frame: Baseline - Pre - Post (7 weeks)
Comparison of adiponectin concentration in the blood plasma at rest across all three measurement points to ensure stability in the monitoring phase and examine change during the intervention phase.
Fasting Resting Metabolic Rate
Time frame: Baseline - Pre - Post (7 weeks)
Comparison of resting metabolic rate (measured by indirect calorimetry) across all three measurement points to ensure stability in the monitoring phase and examine change during the intervention phase.
Post-Prandial Glucose AUC
Time frame: Pre - Post (3 weeks)
Comparison of the area under the plasma glucose curve seen during the 180 minute post-prandial period following a test meal conducted before and after the intervention phase.
Post-Prandial Insulin AUC
Time frame: Pre - Post (3 weeks)
Comparison of the area under the plasma insulin curve seen during the 180 minute post-prandial period following a test meal conducted before and after the intervention phase.
Post-Prandial Ghrelin AUC
Time frame: Pre - Post (3 weeks)
Comparison of the area under the plasma ghrelin curve seen during the 180 minute post-prandial period following a test meal conducted before and after the intervention phase.
Post-Prandial Peptide-YY AUC
Time frame: Pre - Post (3 weeks)
Comparison of the area under the plasma peptide-YY curve seen during the 180 minute post-prandial period following a test meal conducted before and after the intervention phase.
Physical Activity Energy Expenditure
Time frame: Monitoring - Intervention (7 weeks)
Comparison of the mean physical activity energy expenditure values recorded using the Actiheart monitor during the monitoring and intervention phase to see the impact of the three treatments on physically active behaviours.
Physical Activity Intensity
Time frame: Monitoring - Intervention (7 weeks)
Comparison of the mean physical activity intensity values recorded using the Actiheart monitor during the monitoring and intervention phase to see the impact of the three treatments on physically active behaviours.
CLOCK Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
NPAS2 Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
PER1 Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
CRY1 Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
LEP Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
ADIPO-Q Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
IL-6 Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
TNF Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
LPL Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
FABP4 Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
PPARG Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
PPARGC1A Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
SREBP1C Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
FSP27 Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
PRKAA1 Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
ANGPTL4 Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
HSL Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
ATGL Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
PNPLA3 Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
CIDE-A Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
GLUT-4 Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
AKT2 Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
PDK4 Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
SIRT1 Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
SIRT3 Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
UCP2 Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
IGF1R Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
IRS1 Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
IRS2 Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
PIK3R1 Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
ChREBP Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
ACACA Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
FASN Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
ACADM Gene Expression in Subcutaneous Adipose Tissue
Time frame: Pre - Post (3 weeks)
7 secondary outcomes
Fasting Carbohydrate Oxidation
Time frame: Pre - Post (3 weeks)
Fasting Lipid Oxidation
Time frame: Pre - Post (3 weeks)
Fasting Protein Oxidation
Time frame: Pre - Post (3 weeks)
Post-Prandial Resting Metabolic Rate
Time frame: Pre-intervention 60, 120 and 180 minutes after meal - post-intervention 60, 120 and 180 minutes after meal (3 weeks)
Post-Prandial Carbohydrate Oxidation
Time frame: Pre-intervention 60, 120 and 180 minutes after meal - post-intervention 60, 120 and 180 minutes after meal (3 weeks)
Post-Prandial Lipid Oxidation
Time frame: Pre-intervention 60, 120 and 180 minutes after meal - post-intervention 60, 120 and 180 minutes after meal (3 weeks)
Post-Prandial Protein Oxidation
Time frame: Pre-intervention 60, 120 and 180 minutes after meal - post-intervention 60, 120 and 180 minutes after meal (3 weeks)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Apr 2023.
- Derived from this study: PubMed 29394908Templeman I, Thompson D, Gonzalez J, Walhin JP, Reeves S, Rogers PJ, Brunstrom JM, Karagounis LG, Tsintzas K, Betts JA. Intermittent fasting, energy balance and associated health outcomes in adults: study protocol for a randomised controlled trial. Trials. 2018 Feb 2;19(1):86. doi: 10.1186/s13063-018-2451-8.
Related trials for Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
James A Betts, BSc., Ph.D principal investigator
Fellow of the American College of Sports Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Physical Activity Monitoring (Actiheart), Energy Intake Monitoring and Body Weight Monitoring in people with Obesity and Type 2 Diabetes, run by University of Bath at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Body Fat Percentage (time frame: Pre - Post (3 weeks)). The study lists 51 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02498002, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Apr 2023.